Executives from Genomic Health, Meridian Bioscience, and Qiagen provided updates on their companies at the JP Morgan Healthcare Conference in San Francisco.
By detecting as little as one parasite per microliter of whole blood, the test could be used to further future efforts aimed at malaria eradication.
The results affirmed the company's preliminary earnings issued last month.
The company said it expects a 1 percent increase in 2016 revenues, but noted that the results were adversely affected by certain competitive pressures in Q4, among other problems.
The GenomeWeb Index gained more than 5 percent in September, after falling more than 2 percent in August, and outperformed the Nasdaq Biotechnology Index.
The technology, called LAMP, produces DNA at a single temperature and at higher amounts than can be achieved with PCR-based amplification.
Industry executives said they believe ASRs are key components for laboratory directors who need to quickly develop critical diagnostic tests.
A month after Brexit fears pushed the GenomeWeb Index down half a percent, companies rallied on news of an acquisition and better than expected Q2 performances.
The firm saw decreases in its core diagnostics business that were offset in part by revenues from newly-acquired Magellan Diagnostics.
The test is an improved version of one that was approved three years ago, and runs on the firm's illumigene molecular diagnostics platform.
A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.
The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.
Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.